GPCRs in Drug Discovery - Efforts to De-Orphanize Novel GPCR Targets are Increasing
GPCRs in Drug Discovery - Efforts to De-Orphanize Novel GPCR Targets are Increasing
Summary
GBI Research, the leading business intelligence provider, has released its latest research “GPCRs in Drug Discovery - Efforts to De-Orphanize Novel GPCR Targets are Increasing” which provides insights in to the technical and commercial importance of G protein coupled receptors, which are the most important category of receptors in the human body. The report provides a scientific understanding of GPCRs and details the novel research methods being employed in the research of new targets and molecules that can be more effective in treating many indications. A special note on Orphan GPCRs and ways to de-orphanize them is followed by a detailed pipeline analysis to understand the therapeutic classes and indications that are being targeted through GPCRs. The report provides an in-depth analysis of the competitive landscape, including the profiling of top companies and licensing agreements involving GPCR molecules and platform technologies.
Scope
The scope of this report includes:
The report will enhance your decision making capability. It will allow you to:
Summary
GBI Research, the leading business intelligence provider, has released its latest research “GPCRs in Drug Discovery - Efforts to De-Orphanize Novel GPCR Targets are Increasing” which provides insights in to the technical and commercial importance of G protein coupled receptors, which are the most important category of receptors in the human body. The report provides a scientific understanding of GPCRs and details the novel research methods being employed in the research of new targets and molecules that can be more effective in treating many indications. A special note on Orphan GPCRs and ways to de-orphanize them is followed by a detailed pipeline analysis to understand the therapeutic classes and indications that are being targeted through GPCRs. The report provides an in-depth analysis of the competitive landscape, including the profiling of top companies and licensing agreements involving GPCR molecules and platform technologies.
Scope
The scope of this report includes:
- Detailed technical understanding of G protein coupled receptors
- Dedicated sections on Novel research methods being used to improve the GPCR targeted drug discovery and development process
- Understanding of Orphan GPCRs, its importance and novel methods to locate ligands and de-orphanize these receptors
- Pipeline analysis of products at various stages of development targeting receptors classified as GPCRs, including identification of major therapeutic areas and indications
- Analysis and review of important strategic partnerships and licensing agreements in the area of GPCR drug discovery and development
- The report also covers information on the leading market players and the competitive landscape, including specialist companies which have proprietary GPCR platform technology as well as major companies with molecules in not only the NDA Filed stage but also in Phase III
The report will enhance your decision making capability. It will allow you to:
- Develop business strategies by understanding the trends shaping and driving research in the field of GPCRs
- Understand the potential areas of application for GPCR therapies.
- Identify key molecules targeting GPCRs in development based on the therapy.
- Identify the key players investing in GPCR platform technologies
- Optimize your R&D pipeline through identification of novel technologies being used in GPCR research to improve the drug discovery process
- Identify emerging players with a potentially strong product portfolio of molecules targeting GPCRs and create effective counter-strategies to gain a competitive advantage.
- What’s the next big thing in GPCR research? – Identify, understand and capitalize.
Contents
1 TABLE OF CONTENTS1.1 List of Tables
1.2 List of Figures
2 GPCRS IN DRUG DISCOVERY – INTRODUCTION
2.1 GBI Research Report Guidance
3 GPCRS IN DRUG DISCOVERY – OVERVIEW
3.1 Introduction
3.2 GPCR in the Human Genome
3.2.1 Introduction
3.2.2 The Traditional Classification System
3.2.3 The GRAFS Classification System
3.3 Structure of GPCRs
3.3.1 General Structure
3.3.2 Importance of the 7TM
3.4 Structure of G-proteins
3.5 Coupling to G-proteins
3.5.1 Introduction
3.5.2 The Signal Transduction Pathways Involving GPCR
3.6 Second Messengers in the GPCR System
3.6.1 Introduction to Second Messengers
3.6.2 Cyclic Adenosine Monophosphate (cAMP)
3.6.3 Cyclic Guanosine Monophosphate (cGMP)
3.6.4 Diacylglycerol (DAG)
3.6.5 Inositol 1, 4, 5-triphosphate (IP3)
3.6.6 Calcium Ions (Ca2+ )
3.7 Post-Translational Modifications
3.7.1 Glycosylation, Palmitoylation and Phosphorylation
3.7.2 GPCR Desensitization
4 GPCRS IN DRUG DISCOVERY – NOVEL RESEARCH METHODS IN GPCR DRUG DISCOVERY
4.1 Introduction
4.2 Structure-Based Research in GPCR
4.2.1 Introduction
4.2.2 New Avenues
4.2.3 Case Studies
4.3 Fragment-Based Drug Discovery
4.3.1 Introduction
4.3.2 New Avenues
4.3.3 Case Study
4.4 Ligand-Induced Selective Signaling (LiSS)
4.4.1 Introduction
4.4.2 New Avenues
4.4.3 Case Study
4.5 Allosterism and GPCRs
4.5.1 Introduction
4.5.2 New Avenues
4.5.3 Case Studies
4.6 GPCR Dimerization
4.6.1 Introduction
4.6.2 Need to Form Dimers
4.6.3 New Avenues
4.6.4 Case Studies
4.7 GPCR Oligomerization
4.7.1 Introduction
4.7.2 Classification of Oligomers
4.7.3 New Avenues
4.7.4 Case Studies
5 GPCRS IN DRUG DISCOVERY – ORPHAN GPCRS
5.1 Introduction
5.1.1 Orphan GPCRs in the GRAFS Classification System
5.1.2 Orphan GPCRs in the Traditional Classification System
5.2 Current Methods Used in De-orphanization
5.2.1 Introduction
5.2.2 Reverse Pharmacology
5.2.3 Orphan Receptor Strategy
5.2.4 Phylogenetic Analysis and Chemogenomics
5.3 Functional Assays for De-orphanization
5.3.1 Introduction
5.3.2 G protein-dependent Assays
5.3.3 Recent G protein-independent Assays
6 GPCRS IN DRUG DISCOVERY – PIPELINE ANALYSIS BY THERAPEUTIC CLASS
6.1 Central Nervous System
6.1.1 Introduction
6.1.2 Pipeline Profile
6.1.3 Major Indications
6.2 Oncology
6.2.1 Introduction
6.2.2 Pipeline Profile
6.2.3 Major Indications
6.3 Cardiovascular System
6.3.1 Introduction
6.3.2 Pipeline Profile
6.3.3 Major Indications
6.4 Metabolic Disorders
6.4.1 Introduction
6.4.2 Pipeline Profile
6.4.3 Major Indications
6.5 Gastrointestinal Disorders
6.5.1 Introduction
6.5.2 Pipeline Profile
6.5.3 Major Indications
6.6 Respiratory Diseases
6.6.1 Introduction
6.6.2 Pipeline Profile
6.6.3 Major Indications
6.7 Immunology
6.7.1 Introduction
6.7.2 Pipeline Profile
6.7.3 Major Indications
6.8 Women’s Health
6.8.1 Introduction
6.8.2 Pipeline Profile
6.8.3 Major Indications
6.9 Ophthalmology
6.9.1 Introduction
6.9.2 Pipeline Profile
6.9.3 Major Indications
6.10 Genito-Urinary System and Sex Hormones
6.10.1 Introduction
6.10.2 Pipeline Profile
6.10.3 Major Indications
7 GPRCS IN DRUG DISCOVERY – PIPELINE ANALYSIS BY INDICATIONS
7.1 Diabetes
7.1.1 Introduction
7.1.2 Pipeline Profile
7.1.3 Analysis of Major Targets
7.2 Parkinson’s Disease
7.2.1 Introduction
7.2.2 Pipeline Profile
7.2.3 Analysis of Major Targets
7.3 Pain
7.3.1 Introduction
7.3.2 Pipeline Profile
7.3.3 Analysis of Major Targets
7.4 Schizophrenia
7.4.1 Introduction
7.4.2 Pipeline Profile
7.4.3 Analysis of Major Targets
7.5 Obesity
7.5.1 Introduction
7.5.2 Pipeline Profile
7.5.3 Analysis of Major Targets
7.6 Hypertension
7.6.1 Introduction
7.6.2 Pipeline Profile
7.6.3 Analysis of Major Targets
7.7 Asthma
7.7.1 Introduction
7.7.2 Pipeline Profile
7.7.3 Analysis of Major Targets
7.8 Prostate Cancer
7.8.1 Introduction
7.8.2 Pipeline Profile
7.8.3 Analysis of Major Targets
7.9 Chronic Obstructive Pulmonary Disease (COPD)
7.9.1 Introduction
7.9.2 Pipeline Profile
7.9.3 Analysis of Major Targets
7.10 Glaucoma
7.10.1 Introduction
7.10.2 Pipeline Profile
7.10.3 Analysis of Top Targets
8 GPCRS IN DRUG DISCOVERY – COMPETITIVE LANDSCAPE
8.1 GPCRs in Drug Discovery – Major Companies With GPCR Platform Technology
8.1.1 Heptares Therapeutics Ltd.
8.1.2 Receptos Inc.
8.1.3 7TM Pharma A/S
8.1.4 Dimerix Biosciences Pvt. Ltd.
8.1.5 Trevena, Inc.
8.1.6 Cara Therapeutics, Inc.
8.1.7 Addex Pharmaceuticals
8.1.8 Anchor Therapeutics
8.1.9 Domain Therapeutics
8.1.10 Euroscreen S.A.
8.1.11 Omeros Corporation
8.1.12 Arena Pharmaceuticals
8.1.13 Compugen, Ltd.
8.1.14 Tranzyme Pharma, Inc.
8.1.15 Oxagen Limited
8.1.16 Prosarix Ltd.
8.1.17 Acadia Pharmaceuticals Inc.
8.1.18 Actelion Ltd.
8.1.19 AcurePharma AB
8.1.20 DiscoveRx
8.2 GPCRs in Drug Discovery – Top 5 Companies as per Number of Molecules in NDA Filed and in Phase III
8.2.1 Merck & Co., Inc.
8.2.2 Novartis AG
8.2.3 Pfizer Inc.
8.2.4 Eli Lilly and Company
8.2.5 Johnson and Johnson
9 GPCRS IN DRUG DISCOVERY – STRATEGIC CONSOLIDATIONS
9.1 AstraZeneca Enters Into Co-Development Agreement With Heptares
9.2 Heptares Therapeutics Enters Into Option Licensing Agreement With Shire For Adenosine A2A
9.3 Dimerix Bioscience Enters Into Research Agreement With Takeda Cambridge
9.4 Heptares Therapeutics Enters Into Drug Discovery Collaboration With Takeda Pharmaceutical Company Ltd.
9.5 ACADIA Pharmaceuticals Extends Drug Discovery Collaboration With Allergan
9.6 Omeros Expands Licensing Agreement With Daiichi Sankyo
9.7 Domain Therapeutics Enters Into Licensing Agreement With Merck Serono
9.8 Receptos Enters Into Collaboration with Eli Lilly
9.9 Receptos Enters Into Licensing Agreement With Ortho-McNeil-Janssen Pharmaceuticals
9.10 Anchor Therapeutics Enters Into Licensing Agreement with Ortho-McNeil-Janssen
10 GPCRS IN DRUG DISCOVERY – APPENDIX
10.1 Market Definitions
10.2 Abbreviations
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Primary Research
10.3.4 Expert Panel Validation
10.3.5 Section-wise Methodology
10.4 Contact Us
10.5 Disclaimer
10.6 Sources 143
LIST OF TABLES
Table 1: GPCRs in Drug Discovery, The Rhodopsin Receptor Family
Table 2: GPCRs in Drug Discovery, Isoforms of the Heterotrimeric G Proteins
Table 3: GPCRs in Drug Discovery, Types of Mammalian PLC Enzymes
Table 4: GPCRs in Drug Discovery, RhoGEF Regulated by G12/13
Table 5: GPCRs in Drug Discovery, Effects of Protein Kinase C Activation in the Human Body
Table 6: GPCRs in Drug Discovery, Orphan Receptors as per the Traditional Classification System
Table 7: GPCRs in Drug Discovery, De-orphanized GPCRs, 2005-2009
Table 8: GPCRs in Drug Discovery, Pipeline Status of the Top 10 Therapy Areas under GPCRs, 2011
Table 9: GPCRs in Drug Discovery, Pipeline Status of Other Therapy Areas under GPCRs, 2011
Table 10: GPCRs in Drug Discovery, Central Nervous System, Number of Molecules Targeting GPCRs By Phase, 2011
Table 11: GPCRs in Drug Discovery, Central Nervous System, Top 10 Indications By Total Molecules In Pipeline, 2011
Table 12: GPCRs in Drug Discovery, Major Phase III Molecules for CNS Indications, 2011
Table 13: GPCRs in Drug Discovery, Oncology, Number of Molecules Targeting GPCRs By Phase, 2011
Table 14: GPCRs in Drug Discovery, Oncology, Top 10 Indications By Total Molecules In Pipeline, 2011
Table 15: GPCRs in Drug Discovery, Major Phase III Molecules for Oncology Indications, 2011
Table 16: GPCRs in Drug Discovery, Cardiovascular System, Number of Molecules Targeting GPCRs By Phase, 2011
Table 17: GPCRs in Drug Discovery, Cardiovascular System, Top 10 Indications By Total Molecules In Pipeline, 2011
Table 18: GPCRs in Drug Discovery, Major Phase III Molecules for CVS Indications, 2011
Table 19: GPCRs in Drug Discovery, Metabolic Disorders, Number of Molecules Targeting GPCRs By Phase, 2011
Table 20: GPCRs in Drug Discovery, Metabolic Disorders, Top 10 Indications By Total Molecules In Pipeline, 2011
Table 21: GPCRs in Drug Discovery, Major Phase III Molecules for Metabolic Disorders Indications, 2011
Table 22: GPCRs in Drug Discovery, Gastrointestinal Disorders, Number of Molecules Targeting GPCRs By Phase, 2011
Table 23: GPCRs in Drug Discovery, Gastrointestinal Disorders, Top 10 Indications By Total Molecules In Pipeline, 2011
Table 24: GPCRs in Drug Discovery, Major Phase III Molecules for Gastrointestinal Indications, 2011
Table 25: GPCRs in Drug Discovery, Respiratory Diseases, Number of Molecules Targeting GPCRs By Phase, 2011
Table 26: GPCRs in Drug Discovery, Respiratory Diseases, Top 10 Indications By Total Molecules In Pipeline, 2011
Table 27: GPCRs in Drug Discovery, Major Phase III Molecules for Respiratory Diseases Indications, 2011
Table 28: GPCRs in Drug Discovery, Immunology, Number of Molecules Targeting GPCRs By Phase, 2011
Table 29: GPCRs in Drug Discovery, Immunology, Top 10 Indications By Total Molecules In Pipeline, 2011
Table 30: GPCRs in Drug Discovery, Major Phase III Molecules for Immunology Indications, 2011
Table 31: GPCRs in Drug Discovery, Women’s Health, Number of Molecules Targeting GPCRs By Phase, 2011
Table 32: GPCRs in Drug Discovery, Women’s Health, Top 10 Indications By Total Molecules In Pipeline, 2011
Table 33: GPCRs in Drug Discovery, Major Phase III Molecules for Women’s Health Indications, 2011
Table 34: GPCRs in Drug Discovery, Ophthalmology, Number of Molecules Targeting GPCRs By Phase, 2011
Table 35: GPCRs in Drug Discovery, Ophthalmology, Top 10 Indications By Total Molecules In Pipeline, 2011
Table 36: GPCRs in Drug Discovery, Major Phase III Molecules for Ophthalmology Indications, 2011
Table 37: GPCRs in Drug Discovery, Genito-Urinary System and Sex Hormones, Number of Molecules Targeting GPCRs By Phase, 2011
Table 38: GPCRs in Drug Discovery, Genito-Urinary System and Sex Hormones, Top 10 Indications By Total Molecules In Pipeline, 2011
Table 39: GPCRs in Drug Discovery, Major Phase III Molecules for Genito-Urinary System and Sex Hormones Indications, 2011
Table 40: GPCRs in Drug Discovery, Top 10 Indications By Total Molecules in Pipeline, 2011
Table 41: GPCRs in Drug Discovery, Diabetes, Number of Molecules Targeting GPCRs By Phase, 2011
Table 42: GPCRs in Drug Discovery, Parkinson’s Disease, Number of Molecules Targeting GPCRs By Phase, 2011
Table 43: GPCRs in Drug Discovery, Pain, Number of Molecules Targeting GPCRs By Phase, 2011
Table 44: GPCRs in Drug Discovery, Schizophrenia, Number of Molecules Targeting GPCRs By Phase, 2011
Table 45: GPCRs in Drug Discovery, Obesity, Number of Molecules Targeting GPCRs By Phase, 2011
Table 46: GPCRs in Drug Discovery, Hypertension, Number of Molecules Targeting GPCRs By Phase, 2011
Table 47: GPCRs in Drug Discovery, Asthma, Number of Molecules Targeting GPCRs By Phase, 2011
Table 48: GPCRs in Drug Discovery, Prostate Cancer, Number of Molecules Targeting GPCRs By Phase, 2011
Table 49: GPCRs in Drug Discovery, COPD, Number of Molecules Targeting GPCRs By Phase, 2011
Table 50: GPCRs in Drug Discovery, Glaucoma, Number of Molecules Targeting GPCRs By Phase, 2011
Table 51: GPCRs in Drug Discovery, Heptares Therapeutics Ltd., GPCR Research Profile, 2011
Table 52: GPCRs in Drug Discovery, Receptos Inc., GPCR Research Profile, 2011
Table 53: GPCRs in Drug Discovery, 7TM Pharma A/S, GPCR Research Profile, 2011
Table 54: GPCRs in Drug Discovery, Trevena Inc., GPCR Research Profile, 2011
Table 55: GPCRs in Drug Discovery, Cara Therapeutics Inc., GPCR Research Profile, 2011
Table 56: GPCRs in Drug Discovery, Addex Pharmaceuticals, GPCR Research Profile, 2011
Table 57: GPCRs in Drug Discovery, Domain Therapeutics, GPCR Research Profile, 2011
Table 58: GPCRs in Drug Discovery, Euroscreen S.A., GPCR Research Profile, 2011
Table 59: GPCRs in Drug Discovery, Arena Pharmaceuticals, GPCR Research Profile, 2011
Table 60: GPCRs in Drug Discovery, Compugen Ltd., GPCR Research Profile, 2011
Table 61: GPCRs in Drug Discovery, Tranzyme Pharma Inc., GPCR Research Profile, 2011
Table 62: GPCRs in Drug Discovery, Acadia Pharmaceuticals Inc. GPCR Research Profile, 2011
Table 63: GPCRs in Drug Discovery, Actelion Ltd., GPCR Research Profile, 2011
Table 64: GPCRs in Drug Discovery, Merck & Co., Inc. Pipeline Profile, 2011
Table 65: GPCRs in Drug Discovery, Novartis AG Pipeline Profile, 2011
Table 66: GPCRs in Drug Discovery, Pfizer Inc. Pipeline Profile, 2011
Table 67: GPCRs in Drug Discovery, Eli Lilly and Company Pipeline Profile, 2011
Table 68: GPCRs in Drug Discovery, Johnson and Johnson Pipeline Profile, 2011
Table 69: GPCRs in Drug Discovery, AstraZeneca-Heptares Partnership Details
Table 70: GPCRs in Drug Discovery, Heptares-Takeda Partnership Details
Table 71: GPCRs in Drug Discovery, Domain-Merck Licensing Agreement Details 137
LIST OF FIGURES
Figure 1: GPCRs in Drug Discovery, G-Protein Mediated Signaling of 7TM Receptors
Figure 2: GPCRs in Drug Discovery, The GRAFS Classification System
Figure 3: GPCRs in Drug Discovery, The cAMP Signaling Pathway
Figure 4: GPCRs in Drug Discovery, Classification of Oligomers
Figure 5: GPCRs in Drug Discovery, De-orphanization Rate of GPCRs, 2000-2009
Figure 6: GPCRs in Drug Discovery, The Receptor Pharmacology Process for De-orphanization
Figure 7: GPCRs in Drug Discovery, Molecules Targeting GPCRs in Development for Top 10 Therapy Areas, 2011
Figure 8: GPCRs in Drug Discovery, Molecules Targeting GPCRs in Development for Other Therapy Areas, 2011
Figure 9: GPCRs in Drug Discovery, Pipeline Analysis for Molecules Targeting GPCRs by Phase, 2011
Figure 10: GPCRs in Drug Discovery, Central Nervous System, Number of Molecules Targeting GPCRs By Phase, 2011
Figure 11: GPCRs in Drug Discovery, Central Nervous System, Top 10 Indications By Total Molecules In Pipeline, 2011
Figure 12: GPCRs in Drug Discovery, Oncology, Number of Molecules Targeting GPCRs By Phase, 2011
Figure 13: GPCRs in Drug Discovery, Oncology, Top 10 Indications By Total Molecules In Pipeline, 2011
Figure 14: GPCRs in Drug Discovery, Cardiovascular System, Number of Molecules Targeting GPCRs By Phase, 2011
Figure 15: GPCRs in Drug Discovery, Cardiovascular System, Top 10 Indications By Total Molecules In Pipeline, 2011
Figure 16: GPCRs in Drug Discovery, Metabolic Disorders, Number of Molecules Targeting GPCRs By Phase, 2011
Figure 17: GPCRs in Drug Discovery, Metabolic Disorders, Top 10 Indications By Total Molecules In Pipeline, 2011
Figure 18: GPCRs in Drug Discovery, Gastrointestinal Disorders, Number of Molecules Targeting GPCRs By Phase, 2011
Figure 19: GPCRs in Drug Discovery, Gastrointestinal Disorders, Top 10 Indications By Total Molecules In Pipeline, 2011
Figure 20: GPCRs in Drug Discovery, Respiratory Diseases, Number of Molecules Targeting GPCRs By Phase, 2011
Figure 21: GPCRs in Drug Discovery, Respiratory Diseases, Top 10 Indications By Total Molecules In Pipeline, 2011
Figure 22: GPCRs in Drug Discovery, Immunology, Number of Molecules Targeting GPCRs By Phase, 2011
Figure 23: GPCRs in Drug Discovery, Immunology, Top 10 Indications By Total Molecules In Pipeline, 2011
Figure 24: GPCRs in Drug Discovery, Women’s Health, Number of Molecules Targeting GPCRs By Phase, 2011
Figure 25: GPCRs in Drug Discovery, Women’s Health, Top 10 Indications By Total Molecules In Pipeline, 2011
Figure 26: GPCRs in Drug Discovery, Ophthalmology, Number of Molecules Targeting GPCRs By Phase, 2011
Figure 27: GPCRs in Drug Discovery, Ophthalmology, Top 10 Indications By Total Molecules In Pipeline, 2011
Figure 28: GPCRs in Drug Discovery, Genito-Urinary System and Sex Hormones, Number of Molecules Targeting GPCRs By Phase, 2011
Figure 29: GPCRs in Drug Discovery, Genito-Urinary System and Sex Hormones, Top 10 Indications By Total Molecules In Pipeline, 2011
Figure 30: GPCRs in Drug Discovery, Top 10 Indications By Total Molecules in Pipeline, 2011
Figure 31: GPCRs in Drug Discovery, Top 10 Indications By Phase, 2011
Figure 32: GPCRs in Drug Discovery, Diabetes, Number of Molecules Targeting GPCRs By Phase, 2011
Figure 33: GPCRs in Drug Discovery, Diabetes, Major Targets for Pipeline Molecules, 2011
Figure 34: GPCRs in Drug Discovery, Diabetes, Comparison of Major Targets with Stage of Development, 2011
Figure 35: GPCRs in Drug Discovery, Parkinson’s Disease, Number of Molecules Targeting GPCRs By Phase, 2011
Figure 36: GPCRs in Drug Discovery, Parkinson’s Disease, Major Targets for Pipeline Molecules, 2011
Figure 37: GPCRs in Drug Discovery, Parkinson’s Disease, Comparison of Major Targets with Stage of Development, 2011
Figure 38: GPCRs in Drug Discovery, Pain, Number of Molecules Targeting GPCRs By Phase, 2011
Figure 39: GPCRs in Drug Discovery, Pain, Major Targets for Pipeline Molecules, 2011
Figure 40: GPCRs in Drug Discovery, Pain, Comparison of Major Targets with Stage of Development, 2011
Figure 41: GPCRs in Drug Discovery, Schizophrenia, Number of Molecules Targeting GPCRs By Phase, 2011
Figure 42: GPCRs in Drug Discovery, Schizophrenia, Major Targets for Pipeline Molecules, 2011
Figure 43: GPCRs in Drug Discovery, Schizophrenia, Comparison of Major Targets with Stage of Development, 2011
Figure 44: GPCRs in Drug Discovery, Obesity, Number of Molecules Targeting GPCRs By Phase, 2011
Figure 45: GPCRs in Drug Discovery, Obesity, Major Targets for Pipeline Molecules, 2011
Figure 46: GPCRs in Drug Discovery, Obesity, Comparison of Major Targets with Stage of Development, 2011
Figure 47: GPCRs in Drug Discovery, Hypertension, Number of Molecules Targeting GPCRs By Phase, 2011
Figure 48: GPCRs in Drug Discovery, Hypertension, Major Targets for Pipeline Molecules, 2011
Figure 49: GPCRs in Drug Discovery, Hypertension, Comparison of Major Targets with Stage of Development, 2011
Figure 50: GPCRs in Drug Discovery, Asthma, Number of Molecules Targeting GPCRs By Phase, 2011
Figure 51: GPCRs in Drug Discovery, Asthma, Major Targets for Pipeline Molecules, 2011
Figure 52: GPCRs in Drug Discovery, Asthma, Comparison of Major Targets with Stage of Development, 2011
Figure 53: GPCRs in Drug Discovery, Prostate Cancer, Number of Molecules Targeting GPCRs By Phase, 2011
Figure 54: GPCRs in Drug Discovery, Prostate Cancer, Major Targets for Pipeline Molecules, 2011
Figure 55: GPCRs in Drug Discovery, Prostate Cancer, Comparison of Major Targets with Stage of Development, 2011
Figure 56: GPCRs in Drug Discovery, COPD, Number of Molecules Targeting GPCRs By Phase, 2011
Figure 57: GPCRs in Drug Discovery, COPD, Major Targets for Pipeline Molecules, 2011
Figure 58: GPCRs in Drug Discovery, COPD, Comparison of Major Targets with Stage of Development, 2011
Figure 59: GPCRs in Drug Discovery, Glaucoma, Number of Molecules Targeting GPCRs By Phase, 2011
Figure 60: GPCRs in Drug Discovery, Glaucoma, Major Targets for Pipeline Molecules, 2011
Figure 61: GPCRs in Drug Discovery, Glaucoma, Comparison of Major Targets with Stage of Development, 2011
Figure 62: GPCRs in Drug Discovery, Merck & Co., Inc. Pipeline Profile, 2011
Figure 63: GPCRs in Drug Discovery, Novartis AG Pipeline Profile, 2011
Figure 64: GPCRs in Drug Discovery, Pfizer Inc. Pipeline Profile, 2011
Figure 65: GPCRs in Drug Discovery, Eli Lilly and Company Pipeline Profile, 2011 132
COMPANIES MENTIONED
Heptares Therapeutics Ltd.
Receptos Inc.
7TM PHARMA A/S
Dimerix Biosciences Pvt. Ltd.
Trevena, Inc.
Cara Therapeutics, Inc.
Addex Pharmaceuticals
Anchor Therapeutics
Domain Therapeutics
Euroscreen S.A.
Omeros Corporation
Arena Pharmaceuticals
Compugen, Ltd.
Tranzyme Pharma, Inc.
Oxagen Limited
Prosarix Ltd.
Acadia Pharmaceuticals Inc.
Actelion Ltd.
AcurePharma AB
DiscoveRx
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Eli Lilly and Company
Johnson and Johnson
Skip to top